Y-mAbs Therapeutics Past Performance
How has Y-mAbs Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: YMAB is currently unprofitable.
Growing Profit Margin: YMAB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: YMAB is unprofitable, and losses have increased over the past 5 years at a rate of 24.2% per year.
Accelerating Growth: Unable to compare YMAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: YMAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (53%).
Return on Equity
High ROE: YMAB has a negative Return on Equity (-123.84%), as it is currently unprofitable.